Mammalian N-acetylglutamate synthase

Area of Science:

• Biochemistry
• Genetics
• Metabolic Disorders

Background:

• N-Acetylglutamate synthase (NAGS) is a mitochondrial enzyme vital for urea cycle function by producing N-acetylglutamate (NAG).
• NAG allosterically activates carbamylphosphate synthetase I (CPSI), a key enzyme in ammonia detoxification.
• Inherited NAGS deficiency leads to hyperammonemia, a serious metabolic disorder.

Purpose of the Study:

• To identify and characterize the genes responsible for N-Acetylglutamate synthase (NAGS) in mammals.
• To understand the molecular basis of NAGS deficiency and its clinical implications.
• To explore potential therapeutic interventions for hyperammonemia caused by NAGS deficiency.

Main Methods:

• Cloning of mouse and human NAGS genes from liver cDNA libraries.
• Complementation of an argA-deficient Escherichia coli strain to confirm gene function.
• Enzymatic activity confirmation using a stable isotope dilution assay.
• Analysis of protein sequence, mitochondrial targeting signals, and post-translational modifications.
• Structural analysis using hidden Markov models and ongoing protein crystallization.

Main Results:

• The mouse and human NAGS genes were successfully identified and cloned.
• Expressed mammalian NAGS proteins demonstrated enzymatic activity.
• The deduced amino acid sequence revealed a mitochondrial targeting signal and structural domains characteristic of carbamate kinase and acyl-CoA N-acyltransferase.
• Mutations in the NAGS gene were identified in patients with neonatal and late-onset NAGS deficiency.
• Carbamylglutamate, a NAG analog, effectively activates CPSI and shows therapeutic promise.

Conclusions:

• The identification of the NAGS gene provides a basis for genetic diagnostics, including carrier testing and prenatal diagnosis.
• Understanding NAGS function and deficiency is critical for managing hyperammonemia.
• Carbamylglutamate represents a promising therapeutic agent for patients with NAGS deficiency.